Skip to content
SCIENCE

A gel matrix engineered for the oral mucosa.

The gel holds peptides against the mucosa under the tongue and inside the cheek, a vascular route to the bloodstream designed to sidestep gut degradation and first-pass metabolism. GRAS-status ingredients, made in a no-heat process.

THE PLATFORM

Five mechanisms, working together.

The working hypothesis: delivery improves through several complementary effects rather than a single permeation enhancer. Each is an active area of research.

  • 01

    Biointerface modulation

    Interacts with membrane lipids and proteins to open more opportunities for transport across the mucosa.

  • 02

    Enhanced permeation

    Supports transport of larger molecules, shown with high-molecular-weight hyaluronic acid.

  • 03

    Mucoadhesive matrix

    Holds the dose against the mucosa for longer, increasing contact and residence time.

  • 04

    Ionic interactions

    Charge-based effects between the gel, the peptide and the membrane. A research hypothesis.

  • 05

    Molecular organisation

    The no-heat process shapes how actives are dispersed and presented, and protects peptide stability.

FORMATSSublingual · launch formatBuccalTransdermalTopicalInhalable
LABORATORY EVIDENCE

Large molecules, across a human tissue barrier.

MATTEK RECONSTRUCTED TISSUE · 1,300 kDa HYALURONIC ACID

Permeation (ng/mL)

  • 216
  • 254
  • 160
  • 527
  • UNTREATED
  • HA ALONE
  • HA + RAW
  • HA + GELTIDES
2.4× VS UNTREATED · 2.1× VS HA ALONEEarly-stage data. Full summaries under NDA.
LARGE-MOLECULE RESEARCH~35 kDaHCG detected in blood at 4 hoursA glycoprotein hormone far larger than most therapeutic peptides, detected systemically after transdermal application.Early-stage data. Full summaries under NDA.
SAFETY · MATTEKNo tissue damage observedNo structural damage or tissue morphology changes across multiple compounds tested.Early-stage data. Full summaries under NDA.
HUMAN RESEARCH

What we've seen in people so far.

  • Randomised controlled trial (nutrient formulation)

    RANDOMISED · DOUBLE-BLIND · PLACEBO
    RCT

    Improved blood cell counts and sleep quality, with no adverse effects reported.Early-stage data. Full summaries under NDA.

  • Nutrient uptake

    HUMAN EVALUATION
    5 min

    Detected in blood within 5 minutes, with effects sustained for 30 minutes. A nutrient study, not a peptide study.Early-stage data. Full summaries under NDA.

  • Clinical evaluation (blood health formulation)

    CLINICAL EVALUATION
    RBC

    Improved haemoglobin saturation, red blood cell morphology and rheology.Early-stage data. Full summaries under NDA.

  • Peptide observational data

    UNDER NDA
    NDA

    Observational peptide data is available to partners under NDA.Early-stage data. Full summaries under NDA.

EVIDENCE NOTE

Figures reflect supplied study summaries. Observational cohorts are early signals, not controlled trials. Peptide-specific pharmacokinetic studies are [IN PROGRESS / PLANNED]. Full summaries are shared with qualified partners under NDA.

RESEARCH ROADMAP

Building the peptide-specific data set.

Partners in our pilot programme get early access to every study as it reads out.

  1. [Q1 2027]Peptide permeation across mucosal tissue models
  2. [Q2 2027]Pharmacokinetic study: NAD+ sublingual gel vs injection
  3. [Q2 2027]Stability programme for all 8 launch SKUs
  4. [Q3 2027]Partner pilot adherence and outcomes read-out
  5. [Q4 2027]Peer-reviewed publication of platform data